Ultragenyx BLA For UX111 Gene Therapy Accepted By FDA

The FDA has accepted Ultragenyx's resubmitted BLA for UX111, an AAV9 gene therapy seeking accelerated approval for Sanfilippo syndrome Type A, advancing the program into formal review. Acceptance is a de-risking milestone that could move Ultragenyx (RARE) shares modestly (roughly 1-3%) pending review outcomes; monitor for a PDUFA date, advisory committee signals, and any safety/efficacy communications.

Analysis

The FDA has accepted Ultragenyx's resubmitted BLA for UX111, an AAV9 gene therapy seeking accelerated approval for Sanfilippo syndrome Type A, advancing the program into formal review. Acceptance is a de-risking milestone that could move Ultragenyx (RARE) shares modestly (roughly 1-3%) pending review outcomes; monitor for a PDUFA date, advisory committee signals, and any safety/efficacy communications.